Figure 8B reveals that pre-treatment of BDNF-shRNA also notably abrogated the antidepressant-like actions of chiglitazar in the CRS model of depression, as the (CRS + chiglitazar + BDNF-shRNA)-treated mice had evidently more immobility in the FST [ANOVA: F(6, 63) = 21.162, P < 0.01] and TST [ANOVA: F(6, 63) = 25.349, P < 0.01] as well as less sucrose preference [ANOVA: F(6, 63) = 17.894, P < 0.01] than both the (CRS + chiglitazar)-treated and (CRS + chiglitazar + Control-shRNA)-treated mice (n = 10, P < 0.01). The gene discussed is BDNF; the disease is depressive symptom measurement.